Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Breast 1

Conditions

Non-Muscle Invasive Bladder Neoplasms 1Carcinoma, Transitional Cell 1

Interventions

pembrolizumab 164Prednisone 130enzalutamide 127Docetaxel 122Abiraterone Acetate 95Nivolumab 93Gemcitabine 71Sunitinib 67atezolizumab 50abiraterone 50Leuprolide 49acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 48Cisplatin 48radium Ra 223 dichloride 39Sorafenib 39darolutamide 38apalutamide 38Ipilimumab 38Carboplatin 37Prednisolone 33Everolimus 33Axitinib 32cabozantinib 31avelumab 31pazopanib 30Bevacizumab 30Paclitaxel 29enfortumab vedotin 28bicalutamide 28Cyclophosphamide 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Polysorbates × Genitourinary × Clear all
NCT02982395 2019-08-30

Study to Evaluate the Efficacy and Safety Of Intravesical Nanoxel®M In BCG Refractory NMIBC

Samyang Biopharmaceuticals Corporation

Phase 3 Terminated
36 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡